234 related articles for article (PubMed ID: 23056557)
21. Fascin and EMMPRIN expression in primary mucinous tumors of ovary: a tissue microarray study.
Alici O; Kefeli M; Yildiz L; Baris S; Karagoz F; Kandemir B
Pathol Res Pract; 2014 Dec; 210(12):934-8. PubMed ID: 25155376
[TBL] [Abstract][Full Text] [Related]
22. Label-free imaging characteristics of colonic mucinous adenocarcinoma using multiphoton microscopy.
Liu N; Chen J; Xu R; Jiang S; Xu J; Chen R
Scanning; 2013; 35(4):277-82. PubMed ID: 23168617
[TBL] [Abstract][Full Text] [Related]
23. Frozen Section Diagnosis of Ovarian Epithelial Tumors: Diagnostic Pearls and Pitfalls.
Buza N
Arch Pathol Lab Med; 2019 Jan; 143(1):47-64. PubMed ID: 30785337
[TBL] [Abstract][Full Text] [Related]
24. Immunohistochemistry in the Diagnosis of Mucinous Neoplasms Involving the Ovary: The Added Value of SATB2 and Biomarker Discovery Through Protein Expression Database Mining.
Strickland S; Wasserman JK; Giassi A; Djordjevic B; Parra-Herran C
Int J Gynecol Pathol; 2016 May; 35(3):191-208. PubMed ID: 26535987
[TBL] [Abstract][Full Text] [Related]
25. Morphologic, Immunophenotypic, and Molecular Features of Epithelial Ovarian Cancer.
Ramalingam P
Oncology (Williston Park); 2016 Feb; 30(2):166-76. PubMed ID: 26892153
[TBL] [Abstract][Full Text] [Related]
26. Significance of cell cycle regulatory proteins as malignant and prognostic biomarkers in ovarian epithelial tumors.
Lee YH; Heo JH; Kim TH; Kang H; Kim G; Kim J; Cho SH; An HJ
Int J Gynecol Pathol; 2011 May; 30(3):205-17. PubMed ID: 21464733
[TBL] [Abstract][Full Text] [Related]
27. Immunohistological insight into the correlation between neuropilin-1 and epithelial-mesenchymal transition markers in epithelial ovarian cancer.
Adham SA; Al Harrasi I; Al Haddabi I; Al Rashdi A; Al Sinawi S; Al Maniri A; Ba-Omar T; Coomber BL
J Histochem Cytochem; 2014 Sep; 62(9):619-31. PubMed ID: 24850663
[TBL] [Abstract][Full Text] [Related]
28. Mucinous Ovarian Tumors.
Mills AM; Shanes ED
Surg Pathol Clin; 2019 Jun; 12(2):565-585. PubMed ID: 31097115
[TBL] [Abstract][Full Text] [Related]
29. Ovarian mucinous and seromucinous neoplasms: problematic aspects and modern diagnostic approach.
Talia KL; Parra-Herran C; McCluggage WG
Histopathology; 2022 Jan; 80(2):255-278. PubMed ID: 33963606
[TBL] [Abstract][Full Text] [Related]
30. Stromal alterations in ovarian cancers via wavelength dependent Second Harmonic Generation microscopy and optical scattering.
Tilbury KB; Campbell KR; Eliceiri KW; Salih SM; Patankar M; Campagnola PJ
BMC Cancer; 2017 Feb; 17(1):102. PubMed ID: 28166758
[TBL] [Abstract][Full Text] [Related]
31. [Recent advances on ovarian epithelial cancer: definition, subtypes and pathologic features].
Guo DH; Zheng WX
Zhonghua Bing Li Xue Za Zhi; 2013 Sep; 42(9):624-8. PubMed ID: 24314254
[No Abstract] [Full Text] [Related]
32. Endogenous optical biomarkers of ovarian cancer evaluated with multiphoton microscopy.
Kirkpatrick ND; Brewer MA; Utzinger U
Cancer Epidemiol Biomarkers Prev; 2007 Oct; 16(10):2048-57. PubMed ID: 17932352
[TBL] [Abstract][Full Text] [Related]
33. EphA8 is a prognostic marker for epithelial ovarian cancer.
Liu X; Xu Y; Jin Q; Wang W; Zhang S; Wang X; Zhang Y; Xu X; Huang J
Oncotarget; 2016 Apr; 7(15):20801-9. PubMed ID: 26989075
[TBL] [Abstract][Full Text] [Related]
34. Molecular Pathology of Ovarian Epithelial Neoplasms: Predictive, Prognostic, and Emerging Biomarkers.
Ordulu Z; Watkins J; Ritterhouse LL
Clin Lab Med; 2024 Jun; 44(2):199-219. PubMed ID: 38821641
[TBL] [Abstract][Full Text] [Related]
35. Molecular diagnosis in type I epithelial ovarian cancer.
Sadłecki P; Walentowicz-Sadłecka M; Grabiec M
Ginekol Pol; 2017; 88(12):692-697. PubMed ID: 29303228
[TBL] [Abstract][Full Text] [Related]
36. [Clinical validation of multiple biomarkers suspension array technology for ovarian cancer].
Zhao BB; Yang ZJ; Wang Q; Pan ZM; Zhang W; Li L
Zhonghua Fu Chan Ke Za Zhi; 2017 Jan; 52(1):11-19. PubMed ID: 28190310
[No Abstract] [Full Text] [Related]
37. CXCL12 expression by healthy and malignant ovarian epithelial cells.
Machelon V; Gaudin F; Camilleri-Broët S; Nasreddine S; Bouchet-Delbos L; Pujade-Lauraine E; Alexandre J; Gladieff L; Arenzana-Seisdedos F; Emilie D; Prévot S; Broët P; Balabanian K
BMC Cancer; 2011 Mar; 11():97. PubMed ID: 21410972
[TBL] [Abstract][Full Text] [Related]
38. [Significance and expression of PAX8, PAX2, p53 and RAS in ovary and fallopian tubes to origin of ovarian high grade serous carcinoma].
Mao YN; Zeng LX; Li YH; Liu YZ; Wu JY; Li L; Wang Q
Zhonghua Fu Chan Ke Za Zhi; 2017 Oct; 52(10):687-696. PubMed ID: 29060967
[No Abstract] [Full Text] [Related]
39. Prognostic impact of concomitant p53 and PTEN on outcome in early stage (FIGO I-II) epithelial ovarian cancer.
Skírnisdóttir I; Seidal T
Int J Gynecol Cancer; 2011 Aug; 21(6):1024-31. PubMed ID: 21792012
[TBL] [Abstract][Full Text] [Related]
40. Expression of Polypeptide
Murakami M; Kagami S; Nguyen TT; Koi C; Kurita T; Hachisuga T
Anticancer Res; 2017 Jul; 37(7):3911-3915. PubMed ID: 28668894
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
